Cancer Biomarker Market Analysis by Cancer Type (Lung Cancer, Breast, Colorectal, Prostate, Liver), by Application (Diagnostics, Drug Discovery, Personalized Medicine), by Biomolecule (Epigenetic, Proteomic, Metabolic, Genetic Biomarkers), and by Region – Forecast to 2026
- Additional information
- Enquire about
Cancer Biomarker Market Analysis by Cancer Type (Lung Cancer, Breast, Colorectal, Prostate, Liver), by Application (Diagnostics, Drug Discovery, Personalized Medicine), by Biomolecule (Epigenetic, Proteomic, Metabolic, Genetic Biomarkers), and by Region - Forecast to 2026
The global cancer biomarker market size is expected to witness a CAGR of X.X% during the forecast period. Increasing prevalence of cancer, rising awareness of early disease detection, development of novel diagnostic technologies, and demand for personalized medicine are some of the major factors boosting the market. However, factors such as high capital investments, unfavourable reimbursement policies, and limited availability of biological samples & its storage management are restraining the market growth.
Key players operating in the cancer biomarker market are Agilent Technologies (U.S.); Qiagen (Germany); Illumina (U.S.); Becton, Dickinson and Company (U.S.); Bio-Rad Laboratories (U.S.); Myriad Genetics (U.S.); Quest Diagnostics (U.S.); GE Healthcare (U.S.); Thermo Fisher Scientific (U.S.); Sysmex Corporation (Japan); and Abbott Laboratories (U.S.). The major players operating in the market are adopting new product development and mergers & partnerships as major strategies to expand their market presence.
This exhaustive research report focuses on market size and forecast at global, segmental, regional and country level along with key market trends and dynamics from 2017 to 2026. The cancer biomarker market report is categorized into the following segments and subsegments:
Cancer Biomarker Market, By Cancer Type (Revenue, 2017-2026, USD Billion)
- Breast Cancer
- Prostate Cancer
- Cervical Cancer
- Colorectal Cancer
- Lung Cancer
- Liver Cancer
- Other Cancers
Cancer Biomarker Market, By Biomolecule (Revenue, 2017-2026, USD Billion)
- Epigenetic Biomarkers
- Genetic Biomarkers
- Proteomic Biomarkers
- Metabolic Biomarkers
Cancer Biomarker Market, By Application (Revenue, 2017-2026, USD Billion)
- Drug Discovery
- Personalized Medicine
Cancer Biomarker Market, By Region (Revenue, 2017-2026, USD Billion)
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of APAC
- Latin America
- Rest of LATAM
- Middle East & Africa
- South Africa
- Saudi Arabia
- Rest of MEA
Key questions addressed by the research report-
- What are the current market trends (2017 to 2020) and future market forecast from 2021 to 2026 for the market?
- What are the market dynamics and probable opportunities for market players during the forecast period?
- Initiatives undertaken my market players to address the COVID-19 impact to sustain in the competitive market.
- Which geographies have immense opportunities in different segments and sub-segments of the market?
- What are the recent strategies adopted by market players such as product launch, partnership, agreement, collaboration, merger & acquisition, and geographical expansion?